315 related articles for article (PubMed ID: 17320271)
1. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study.
Bohnen AM; Groeneveld FP; Bosch JL
Eur Urol; 2007 Jun; 51(6):1645-52; discussion 1652-3. PubMed ID: 17320271
[TBL] [Abstract][Full Text] [Related]
2. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study.
Bosch JL; Bohnen AM; Groeneveld FP
Eur Urol; 2004 Dec; 46(6):753-9. PubMed ID: 15548443
[TBL] [Abstract][Full Text] [Related]
3. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
Chung BH; Hong SJ; Cho JS; Seong DH
BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
[TBL] [Abstract][Full Text] [Related]
4. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels.
Tanaka N; Fujimoto K; Chihara Y; Torimoto M; Hirao Y; Konishi N; Saito I
Prostate Cancer Prostatic Dis; 2007; 10(3):274-8. PubMed ID: 17339878
[TBL] [Abstract][Full Text] [Related]
5. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I
Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178
[TBL] [Abstract][Full Text] [Related]
6. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
7. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
[TBL] [Abstract][Full Text] [Related]
8. A higher PSA-density cut-off level in patients with intermediate PSA values for the early detection of prostate cancer.
Mochtar CA; Rahardjo D; Umbas R
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():514-22. PubMed ID: 10895203
[TBL] [Abstract][Full Text] [Related]
9. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.
Sözen S; Eskicorapci S; Küpeli B; Irkilata L; Altinel M; Ozer G; Uygur C; Alkibay T; Ozen H
Eur Urol; 2005 Mar; 47(3):302-7. PubMed ID: 15716190
[TBL] [Abstract][Full Text] [Related]
10. Predictive properties of serum-prostate-specific antigen testing in a community-based setting.
Jacobsen SJ; Bergstralh EJ; Guess HA; Katusic SK; Klee GG; Oesterling JE; Lieber MM
Arch Intern Med; 1996 Nov; 156(21):2462-8. PubMed ID: 8944739
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
[TBL] [Abstract][Full Text] [Related]
12. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
[TBL] [Abstract][Full Text] [Related]
13. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
14. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK
Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
[TBL] [Abstract][Full Text] [Related]
15. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
[TBL] [Abstract][Full Text] [Related]
16. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
Urology; 2004 Mar; 63(3):492-8. PubMed ID: 15028444
[TBL] [Abstract][Full Text] [Related]
17. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
Garzotto M; Hudson RG; Peters L; Hsieh YC; Barrera E; Mori M; Beer TM; Klein T
Cancer; 2003 Oct; 98(7):1417-22. PubMed ID: 14508828
[TBL] [Abstract][Full Text] [Related]
18. Age specific reference levels of serum prostate-specific antigen, prostate volume and prostate specific antigen density in healthy Iranian men.
Khezri AA; Shirazi M; Ayatollahi SM; Lotfi M; Askarian M; Ariafar A; Afrasiabi MA
Iran J Immunol; 2009 Mar; 6(1):40-8. PubMed ID: 19293477
[TBL] [Abstract][Full Text] [Related]
19. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
[TBL] [Abstract][Full Text] [Related]
20. Histological diagnosis of prostate cancer in Korean men aged 70-79 years.
Shim HB; Lee SE; Park HK; Ku JH
Jpn J Clin Oncol; 2007 Oct; 37(10):782-7. PubMed ID: 17913831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
